Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nuccitelli R et al. - The pulses penetrate into the interior of every tumor cell and initiate DNA fragmentation and apoptosis while at the same time reducing blood flow to the tumor. This new physical tumor therapy is drug free, highly localized, uses low energy, has no significant side effects and results in very little scarring.

Related Articles

Loss of SNF5 expression correlates with poor patient survival in melanoma
Clinical Cancer Research, 10/12/09    Relevance Score: 97%

Slow-growing melanoma: a dermoscopy follow-up study
British Journal of Dermatology, 10/05/09    Relevance Score: 93%

Dormancy of metastatic melanoma
Pigment Cell & Melanoma Research, 11/11/09    Relevance Score: 91%

ADAM10 Is Upregulated in Melanoma Metastasis Compared with Primary Melanoma
Journal of Investigative Dermatology, 11/03/09    Relevance Score: 91%

KIT as a Therapeutic Target in Melanoma
Journal of Investigative Dermatology, 10/23/09    Relevance Score: 90%

Today in Dermatologic Oncology...keeping you current

JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling
Oncogene, 12/04/09

Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application
Journal of the European Academy of Dermatology and Venereology, 12/02/09

Self-reported screening for skin cancer in Austria
European Journal of Dermatology, 12/02/09

Today in Pharmacology/Therapy...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address